A two-phased, randomized, double blind, placebo-controlled study of ECP002A (delta9-THC) to determine safety, tolerability and efficacy in Multiple Sclerosis patients suffering from spasticity and pain.

Trial Profile

A two-phased, randomized, double blind, placebo-controlled study of ECP002A (delta9-THC) to determine safety, tolerability and efficacy in Multiple Sclerosis patients suffering from spasticity and pain.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2014

At a glance

  • Drugs Dronabinol (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Echo Pharmaceuticals
  • Most Recent Events

    • 11 Jul 2013 Study was successfully completed with positive effects on spasticity and pain, according to an Echo Pharmaceuticals media release.
    • 04 May 2013 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
    • 14 Mar 2013 Status changed from recruiting to active, no longer recruiting, as reported in an Echo Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top